低相对分子质量肝素用于冠脉介入治疗的有效性及安全性  

The Efficacy and Safety of Coronary Intervention Therapy Using Low Molecular Weight Heparin

作　　者：白秀萍[1] 宫照伟[1] 王蕾 程荣超[1] 孙超宇[1] 孙桂志[1] 

机构地区：[1]哈尔滨医科大学附属第四医院心内科,哈尔滨150001 [2]哈尔滨市红十字中心医院心内科

出　　处：《血栓与止血学》2016年第1期13-15,共3页Chinese Journal of Thrombosis and Hemostasis

基　　金：黑龙江省教育厅科学技术研究项目;编号:12521171

摘　　要：目的观察低相对分子质量肝素(LMWH)用于冠脉介入治疗的有效性及安全性。方法入院我院心内科2013年至2015年间行冠脉造影或冠脉支架植入术的患者共300例,随机分为实验组和对照组,每组150例。实验组在冠脉造影或介入治疗术中使用LMWH,对照组给予常规剂量的普通肝素,比较两组患者术后30天内的主要终点事件(心肌梗死、心源性猝死、急诊血运重建、卒中)和次要终点事件(穿刺部位血肿、假性动脉瘤、出血)的发生率。结果在主要终点事件上两组无统计学差异,实验组次要终点事件的发生率低于对照组。结论 LMWH用于冠脉介入治疗安全、有效。Objective To observe the efficacy and safety of coronary intervention therapy using low molecular weight heparin（LMWH）. Methods 300 patients with coronary angiography or coronary stent im- plantation,which were admitted in Department of Cardiology in our hospital between 2013 and 2015, divided into experiment and control groups randomly, and each group has 150 samples. The experiment group used the LMWH during coronary angiography or coronary intervention therapy, and the control group used the with con- ventional dose. Compared the incidence of primary endpoint events （myocardial infarction, sudden cardiac death, emergency revascularization, apoplexy） and secondary endpoint events （ Puncture site hematoma, pseud- oaneurysm, hemorrhage）between experiment group and control group within 30 days post surgery. Results There is no significant difference in primary endpoint events between experiment group and control group, how- ever,the incidence rate in secondary endpoint events manifested lower in experiment group compared with the group of control. Conclusion Coronary intervention therapy using LMWH is safe and effective.

关 键 词：冠脉介入治疗 安全性 有效性 

分 类 号：R541.4[医药卫生—心血管疾病]